focus -WSS

focus

author：Wikipedia 2025-09-28 02:28:49 - browse：6

Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.

The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.

First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Community addresses injustice for Long Island mothers

focus

explore

WSS

Listen: Biogen's messy board & Laronde's data problem

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Did the public have the right to know Arthur Ashe had AIDS?

Kaiser's Risant Health gobbled up Geisinger. Who is next?

hotspot

focus

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Trump demands the U.S. pay no more for drugs than other countries … again

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO: AstraZeneca says CAR

Sports medicine is finally prioritizing gender equality

At ASCO, AstraZeneca reports strong data for breast cancer drug

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

knowledge

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Meta looks to target Twitter with a rival app called Threads

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO: AstraZeneca says CAR

focus

knowledge

explore

leisure time